Neoadjuvant Immunoradiation for Stage IIIA Resectable Non-Small Cell Lung
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.
- 11 Dec 2017 Planned initiation date changed from 1 Sep 2017 to 11 Dec 2017.
- 04 Aug 2017 New trial record